Rivaroxaban and Risk of Venous Thromboembolism in P
Peripheral Artery Disease After Lower Extremity Revas

JAMA Network Open

5, e2215580-e2215580

DOI: 10.1001/jamanetworkopen.2022.15580

Citation Report

#	Article	IF	Citations
1	Prevention of Arterial and Venous Thrombotic Events in Symptomatic Peripheral Arterial Disease Patients After Lower Extremity Revascularization in the VOYAGER PAD Trial: Dual Anticoagulant/Antiplatelet Regimen vs Antiplatelet Therapy Alone. Journal of Thrombosis and Haemostasis, 2022, 20, 1193-1205.	5.0	15
2	Integrating Mechanisms in Thrombotic Peripheral Arterial Disease. Pharmaceuticals, 2022, 15, 1428.	6.1	14
3	Rivaroxaban schützt pAVK-Patienten vor venösen Thrombembolien. Gefäßmedizin Scan - Zeitschrift Für Angiologie Gefäßchirurgie Diagnostische Und Interventionelle Radiologie, 2022, 9, 270.	0.0	0
4	Impact of Venous Thromboembolism on Incidence of Arterial Thromboembolism - An Analysis of German Outpatient Claims Data. Thrombosis Research, 2023, 226, 9-17.	2.9	12
5	Prescribing of Low-Dose Rivaroxaban in Patients With Atherosclerotic Cardiovascular Disease in the United Kingdom and the Netherlands. British Journal of Clinical Pharmacology, 2023, 89, 2263-2271.	3.0	0
6	Gene Therapeutic Strategies for Peripheral Artery Disease and New Opportunities Provided by Adeno-Associated Virus Vectors. Arteriosclerosis, Thrombosis, and Vascular Biology, 2023, 43, 836-851.	7.9	29
7	Peripheral Arterial Disease and the Pharmacist's Role in Management. Journal of Clinical Pharmacy and Therapeutics, 2023, .	1.0	0
8	Cardiovascular Insights for the Appropriate Management of Chronic Venous Disease: A Narrative Review of Implications for the Use of Venoactive Drugs. Advances in Therapy, 2023, 40, 5137-5154.	5.0	24
9	Clinical Outcomes in Elderly Atrial Fibrillation Patients at Increased Bleeding Risk Treated With Very Low Dose vs. Regular-Dose Non-Vitamin K Antagonist Oral Anticoagulants: A Nationwide Cohort Study. European Heart Journal - Cardiovascular Pharmacotherapy, 2023, 9, 681-691.	5.0	22
10	Rivaroxaban Plus Aspirin vs. Dual Antiplatelet Therapy in Endovascular Treatment in Peripheral Artery Disease and Analysis of Medication Utilization of Different Lesioned Vascular Regions. Frontiers in Surgery, 2023, 10, 1285553.	2.2	3
11	How I Treat the Co-Occurrence of Venous and Arterial Thromboembolism: Anticoagulation, Antiplatelet Therapy, or Both?. Blood, 2024, 143, 2351-2362.	10.6	17
12	Comparative Outcomes of Peripheral Vascular Interventions in Patients on Chronic Anticoagulation With Factor Xa Inhibitors and Vitamin K Antagonists. Annals of Vascular Surgery, 2024, 104, 185-195.	1.8	2
13	Effects of Sini Decoction-Mediated Cellular Mitochondrial Autophagy on M1 Macrophage Polarization and Its Impact on a Mouse Model of Peripheral Artery Disease. Journal of Bioenergetics and Biomembranes, 2025, 57, 1-15.	3.9	1
14	Managing Patients With a History of Arterial Disease and New Venous Thromboembolism. Hematology, 2025, 2025, 22-33.	2.5	1
15	Antithrombotic Therapy in Lower Extremity Peripheral Artery Disease Patients With Venous Thromboembolism: A Nationwide Cohort Study. Research and Practice in Thrombosis and Haemostasis, 2026, 10, 103291.	3.3	1
16	A Systematic Review of Anticoagulants Evaluating Efficacy and Safety in Thromboembolic Disease. International Journal of Community Medicine and Public Health, 2026, 13, 912-921.	0.4	0
17	Anticoagulation in Peripheral Artery Disease: Scoping Review With ❄SAIMSARA. , 2026, .		0
18	Preliminary Clinical Observation of a Novel Anticoagulation Regimen in the Acute Phase of Thromboangiitis Obliterans (Buerger's Disease). Asian Journal of Surgery, 2026, .	0.7	0

#	Article	IF	Citations
19	Lipid-Lowering Therapy in Venous Thromboembolism: A Clinical Consensus Statement of the ESC Working Group on Aorta and Peripheral Vascular Diseases, the ESC Working Group on Cardiovascular Pharmacotherapy, the ESC Working Group on Pulmonary Circulation & Right Ventricular Function, and the European Society of Vascular Medicine (ESVM). European Journal of Preventive Cardiology, 2026, .	6.1	0